You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

CLINICAL TRIALS PROFILE FOR FINACEA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Finacea

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01038869 ↗ Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Bayer Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01038869 ↗ Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Derm Research, PLLC Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01139008 ↗ Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01139047 ↗ Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01631656 ↗ Combination Gel and Vascular ND in Mild to Moderate Rosacea Completed Bayer N/A 2010-07-01 This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for laser, subjects will be screened for study enrollment and topical treatment of their rosacea at the Screening/Baseline visit. All subjects will receive Finacea 15% gel and will be instructed to apply the study drug to one half of the face, twice daily. Drug application will be modified just prior to and after the subjects' laser treatment to reduce irritation. Subjects will undergo Vascular Nd:Yag laser therapy to involved areas over the whole face two weeks after initiating Finacea treatment. Subjects will continue to use Finacea gel to one half of the face for the duration of the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Finacea

Condition Name

Condition Name for Finacea
Intervention Trials
Rosacea 6
Skin Manifestations 2
Post Inflammatory Hyperpigmentation 1
Rosacea, Papulopustular 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Finacea
Intervention Trials
Rosacea 8
Skin Manifestations 2
Alopecia Areata 1
Alopecia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Finacea

Trials by Country

Trials by Country for Finacea
Location Trials
United States 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Finacea
Location Trials
North Carolina 5
Texas 3
Kentucky 3
Virginia 2
South Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Finacea

Clinical Trial Phase

Clinical Trial Phase for Finacea
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 1 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Finacea
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Finacea

Sponsor Name

Sponsor Name for Finacea
Sponsor Trials
Bayer 3
Derm Research, PLLC 2
Galderma Laboratories, L.P. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Finacea
Sponsor Trials
Industry 12
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

FINACEA: Clinical Trials, Market Analysis, and Projections

Introduction to FINACEA

FINACEA, a topical foam formulation of azelaic acid at a concentration of 15%, is approved for the treatment of inflammatory papules and pustules of mild to moderate rosacea. Here, we delve into the clinical trials, market analysis, and future projections for this medication.

Clinical Trials Overview

Phase III Clinical Trials

The approval of FINACEA was based on data from two identical Phase III multi-center, double-blind, randomized, placebo-controlled, parallel-group studies involving 333 patients with mild to moderate papulopustular rosacea. These studies demonstrated the efficacy and safety of FINACEA when applied twice daily for 12 weeks. The results showed significant improvements in the primary characteristics of rosacea, including a 58% decrease in lesion count and significant reductions in erythema severity[4].

Safety and Tolerability

The clinical trials also evaluated the safety and tolerability of FINACEA. The drug-related side effects were generally mild to moderate and included cutaneous reactions such as stinging, tingling, burning, pruritus, and dry skin. No phototoxicity or photoallergenicity were reported in human dermal safety studies[1][4].

Regulatory Meetings and Compliance

Throughout the development process, Bayer HealthCare, the applicant, had several meetings with the FDA to ensure compliance with regulatory requirements. These meetings included pre-IND, guidance, end-of-Phase 2, and pre-NDA meetings. The studies were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice[1].

Market Analysis

Global Topical Drug Delivery Market

The global topical drug delivery market, which includes products like FINACEA, is expected to experience healthy growth due to the rising prevalence of skin disorders and the increasing preference for topical treatments. North America is anticipated to hold a significant share of this market, driven by technological advancements and new product developments. The Asia Pacific region is also expected to grow, fueled by an increasing geriatric population and rising healthcare expenditure[2].

Rosacea Treatment Market

Within the rosacea treatment market, the topical segment dominates due to its convenience and effectiveness in treating localized symptoms. FINACEA, as a topical foam, fits into this preferred treatment category. The U.S. and European markets are key drivers, with high healthcare expenditure and increasing awareness of rosacea treatments contributing to market growth[5].

Market Projections

Revenue Growth

The global rosacea treatment market, which includes FINACEA, is projected to grow at a CAGR of 7.1% from 2025 to 2030, reaching an estimated value of over USD 2.8 billion by 2030. The topical segment, in particular, is expected to maintain its dominance due to ongoing research into new topical agents and the preference for localized treatments[5].

Regional Growth

North America, particularly the U.S., is expected to continue its dominance in the rosacea treatment market, driven by high healthcare expenditure and access to advanced medical treatments. Europe will also hold a substantial market share, driven by increasing awareness and accessibility to dermatological care[5].

Competitive Landscape

The market for rosacea treatments is competitive, with antibiotics currently dominating due to their established role as first-line therapies. However, the alpha agonists segment, which targets facial erythema, is anticipated to grow at the highest CAGR of 7.5% over the forecast period. FINACEA, with its efficacy in treating inflammatory papules and pustules, will continue to be a significant player in this market[5].

Key Trends and Factors

Increasing Prevalence of Skin Disorders

The rising prevalence of skin disorders, including rosacea, is a key driver for the growth of the topical drug delivery market and, by extension, FINACEA.

Technological Advancements

Advancements in drug delivery technologies and the increasing adoption of new treatments are expected to boost the market for FINACEA.

Patient Preference and Awareness

The preference for topical treatments and increasing awareness of rosacea among patients and healthcare providers are significant factors contributing to the market growth of FINACEA[2][5].

Challenges and Opportunities

Product Recalls and Safety Concerns

While the market is expected to grow, product recalls and safety concerns can negatively impact consumer confidence and market growth. However, FINACEA has demonstrated a strong safety profile in clinical trials[2].

Emerging Markets

The Asia Pacific region presents a significant opportunity for growth, driven by an increasing geriatric population and rising healthcare expenditure. Expanding into these markets could further boost the sales of FINACEA[2].

Key Takeaways

  • Clinical Efficacy: FINACEA has demonstrated significant efficacy in treating mild to moderate papulopustular rosacea in Phase III clinical trials.
  • Market Growth: The global rosacea treatment market and the topical drug delivery market are expected to grow, driven by increasing prevalence of skin disorders and technological advancements.
  • Regional Dominance: North America and Europe will continue to be key markets, with the Asia Pacific region showing promising growth potential.
  • Competitive Landscape: FINACEA will compete in a market dominated by antibiotics but will benefit from its unique formulation and efficacy.

FAQs

1. What is FINACEA used for?

FINACEA is used for the treatment of inflammatory papules and pustules of mild to moderate rosacea.

2. What were the key findings of the Phase III clinical trials for FINACEA?

The Phase III trials showed a 58% decrease in lesion count and significant reductions in erythema severity when FINACEA was applied twice daily for 12 weeks.

3. What are the common side effects of FINACEA?

Common side effects include mild to moderate cutaneous reactions such as stinging, tingling, burning, pruritus, and dry skin.

4. How does FINACEA fit into the broader topical drug delivery market?

FINACEA is part of the topical segment, which dominates the market due to its convenience and effectiveness in treating localized symptoms.

5. What are the growth projections for the rosacea treatment market?

The global rosacea treatment market is projected to grow at a CAGR of 7.1% from 2025 to 2030, reaching an estimated value of over USD 2.8 billion by 2030.

Cited Sources

  1. FDA Medical Review: "207071Orig1s000 - FINACEA (azelaic acid) Foam, 15%"[1]
  2. Biospace: "Topical Drug Delivery Market Key Trends, Potential, Growth and Competitive Analysis"[2]
  3. Nova One Advisor: "Clinical Trials Market Size, Share & Analysis Report, 2024-2033"[3]
  4. Health Canada: "Summary Basis of Decision for Finacea"[4]
  5. Grand View Research: "Rosacea Treatment Market Size | Industry Report, 2030"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.